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ABSTRACT 
 
Current evidence suggests that transcriptional and epigenomic reprogramming events, 
triggered by transcription factors and chromatin-modifying co-regulators, are of central 
importance for disease development. G-protein pathway suppressor 2 (GPS2) is a key 
component of the HDAC3 co-repressor complex that has been earlier implicated in 
cholesterol homeostasis and anti-inflammatory crosstalk. More recent work revealed that 
the expression and function of GPS2 is altered in obese humans and correlated to the 
inflammation status and the risk for developing type 2 diabetes. Although this potentially 
suggests the involvement of GPS2 in metaflammation, i.e. closely linked metabolic and 
inflammatory disease pathways, the underlying mechanisms and the precise role of GPS2 
remained unknown. The aim of this thesis was to characterize the functions of GPS2 at the 
molecular and physiological level with an emphasis on obesity-associated inflammation, 
insulin resistance, and fatty liver disease. 
 
In Paper I, we identified GPS2 as a key regulator of ABCA1-dependent cholesterol efflux 
in inflammatory macrophages. This study potentially implicates the GPS2-ABCA1 axis in 
linking obesity and type 2 diabetes to cardiovascular diseases. 
 
In Paper II, we identified GPS2-repressed pro-inflammatory enhancers and deeply 
characterized enhancer structure and function at the Ccl2 gene locus in macrophages. The 
study revealed that GPS2-repressed enhancers are non-redundant and that inhibiting 
enhancer-transcribed eRNAs reduced gene expression, thus suggesting eRNA function.  
 
In Paper III, we characterized macrophage-specific Gps2 knockout mice along with in 
vitro models and expression analysis in humans to identify a potent anti-inflammatory role 
of GPS2 and the underlying genomic actions. Upon diet-induced obesity, Gps2 knockout 
mice display hallmarks of metaflammation typical for obese humans, i.e. elevated 
inflammation and insulin resistance.  
 
In Paper IV, we describe hitherto unknown liver functions of GPS2 in the development of 
the non-alcoholic fatty liver disease. Through integrated genomic and phenotypic 
characterization of hepatocyte-specific Gps2 knockout mice, we found that GPS2 
specifically antagonizes the fatty acid receptor PPARa. Thus, the selective modulation of 
GPS2-PPARa interactions could be of therapeutic interest for future interventions.  
 
In conclusion, this thesis revealed novel insights into the multifaceted regulatory roles of 
GPS2 in altering epigenomes and transcription linked to metabolic and inflammatory 
processes. These insights should help to better understand the development of obesity, type 
2 diabetes, atherosclerosis, and fatty liver disease, and they may help to define novel 
therapeutic strategies. 
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1  INTRODUCTION 
1.1    Macrophages 
 
Macrophages are the crucial component of innate immunity and play an important role in 
tissue host defense and homeostasis [1]. Tissue macrophages provide the first defense 
against microorganisms and protect the body from infection through the release of 
cytokines [1-5]. Tissue-resident macrophages include brain microglia, lung alveolar 
macrophages, liver Kupffer cells, spleen macrophages, adipose tissue macrophages, kidney 
intraglomerular mesangial macrophages and intestinal macrophages, amongst others. They 
are mainly developed from progenitor cells in the yolk sac or from bone marrow 
hematopoietic stem cells [6].  
The differentiation and maturation of tissue-resident macrophages require precise 
regulation by a group of growth factors and transcription factors (TFs) such as PU.1 and 
Runt-related transcription factor 1 (RUNX1) [6-10]. As shown in Figure 1, tissue-resident 
macrophages are functionally different dependent on the tissue-specific signals and the 
Figure 1.  Tissue `imprinting´ generates macrophage heterogeneity.  
 
Reprinted from Nature reviews immunology, Vol. 11, p. 723-737. Peter J. Murray and Thomas A. Wynn, Protective 
and pathogenic functions of macrophage subsets, doi:10.1038/nri3073, Copyright 2011, with permission from Nature. 
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surrounding microenvironment [9, 10].  Disturbing this process could alter normal 
macrophage function, leading to diseases such as infections, tumors, metabolic and 
autoimmunity diseases [10-12].  
1.1.1 Macrophage lipid metabolism 
 
As a defensive cell type, macrophages mainly participate in phagocytosis, muscle 
regeneration, wound healing, limb regeneration, iron homeostasis, lipid metabolism, and 
pigment retention. All these processes are dynamically balanced to maintain the health 
status [13-15].   
 
Three major types of pathways in mammals cooperatively regulate the lipid (i.e. 
triglycerides and cholesterol) metabolism. These include 1) exogenous pathways, 2) 
endogenous pathways, and 3) reverse cholesterol transport (RCT). The exogenous 
pathways refer to the process of intestinal uptake of chylomicrons and their transport in the 
bloodstream to the peripheral tissues where the chylomicrons are further degraded to free 
fatty acids and cholesterol. In contrast, the endogenous pathways mainly represent the very 
low-density lipoproteins (VLDLs) synthesis and transport from the liver to the peripheral 
tissues (mainly adipose tissues), where VLDLs are degraded to free fatty acids and low-
density lipoproteins (LDLs) [5, 16]. Then LDLs deliver cholesterol and circulating 
triglycerides to the liver again. RCT is a complex process resulting in the cholesterol 
transport from peripheral tissues to the liver in the form of high-density lipoproteins (HDL) 
[17].  
 
RCT is essential for cell homeostasis as most cells cannot metabolize cholesterol. 
Macrophages are the critical cells which regulate and metabolize cholesterol through RCT. 
Macrophages assimilate cholesterol via phagocytosis and macropinocytosis and export the 
endogenous cholesterol to HDL via the RCT process. Disruption of this process leads to 
macrophage cholesterol accumulation which generates foam cells, an early risk factor to 
cause plaque formation and atherosclerosis development [14, 18]. ATP-binding cassette 
transporter A1 (ABCA1) and ATP-binding cassette transporter G1 (ABCG1) are the major 
transporters to regulate cholesterol efflux in the macrophages with the help of lipid-poor 
apoA1 (Figure 2). After circulation, the mature HDL transport the cholesteryl esters to the 
liver in the form of triglycerides, LDL and VLDL. These lipoproteins can be further 
transferred and secreted by bile acids [5, 17, 18]. 
  3 
 
ABCA1 and ABCG1 ablation could significantly reduce the RCT both in vitro and in vivo, 
which resulted in the development of atherosclerotic lesions [19, 20]. The functional 
difference between ABCA1 and ABCG1 in RCT is that ABCA1 transports cholesterol to 
HDL and ABCG1 transports cholesterol to apoA1 [20].  Liver X receptors (LXRa and 
LXRb) are the key TF for the regulation of ABCA1/G1 gene expression. LXRs are ligand-
dependent TFs which control cholesterol homeostasis in liver and peripheral tissues.  LXRs 
specifically recognize the LXR response element (LXRE) and bind to gene promoters and 
enhancers in the form of LXR/ Retinoid X receptor (RXR) heterodimers. The endogenous 
LXR ligands are oxysterols and oxidized cholesterol while the synthetic LXR ligands 
T0901317 and GW3965 are widely used in research, which makes LXRs potential drug-
targetable candidates for the treatment of atherosclerosis and metabolic syndrome [14, 21-
23].  
1.1.2 Macrophage inflammation 
 
The commonly described macrophage polarization states are classical M1 polarization and 
alternative M2 polarization (Figure 3) [24-26]. The classical M1 activation, which can be 
induced by toll-like receptor 4 (TLR4) ligands, interferon-g (IFNg) or tumor necrosis factor-
Figure 2.  Macrophage-mediated reverse cholesterol transport (RCT). 
 
Reprinted from Nature Medicine, Vol. 18, p.1346-1347. Peter Jay W Heinecke, A new era for quantifying HDL and 
cardiovascular risk? DOI: 10.1038/nm.2930, Copyright 2012, with permission from Springer Nature. 
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a (TNFa), is characterized by a high level of antigen presentation, high expression of pro-
inflammatory cytokines and chemokines such as C-C motif chemokine ligand 2 (Ccl2) and 
Tnfa, high production of nitric oxide (NO) and reactive oxygen intermediates (ROI) [25-
27]. In contrast, the alternative M2 activation, which can be induced by interleukin 4/13 
(IL4/IL13), is characterized by a high expression of anti-inflammatory cytokines such as 
interleukin 10 (IL10) and promotes tissue remodeling and repair [27-29]. In mice models, 
M2 macrophages display high expression of signature genes including found in 
inflammatory zone 1 (Fizz1), arginase (Arg1) and chitinase-like protein 3 (Chil3). M2 
macrophages can be further subdivided into subtypes based on different signaling pathways 
and chemokine expression [26]. For example, IL4/IL13 signaling pathways induce the M2a 
macrophages, which have high expression of Ccl17, Ccl22, and Ccl24. M2b macrophages 
are immunity-related, can be induced by lipopolysaccharide (LPS) and have a relatively 
high expression of Ccl1, interleukin 6 (Il6), Tnfa and Il10. Despite the expression of pro-
inflammatory genes, the M2b macrophages protect mice from LPS toxicity [30]. IL10 also  
mediates the M2c activation with high expression of Ccl16, Ccl18 and, transforming 
growth factor (Tgfb) [26]. 
 
Figure 3. Macrophage activation and polarization. 
  
Reprinted from J Transl Med, Vol. 15, Kely Campos Navegantes et al., Immune modulation of some autoimmune 
diseases: the critical role of macrophages and neutrophils in the innate and adaptive immunity. doi:  10.1186/s12967-
017-1141-8, Copyright 2017, Used under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/). 
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Different polarized macrophage subtypes are functionally different in response to 
environment-derived signals. LPS/ IFNg-induced M1 macrophages are involved in T-cell 
responses 1 (Th1) responses, type I inflammation, tumor resistance, and clearing pathogens. 
In contrast, IL4/IL13 medicated M2a macrophages are involved in type II inflammation, 
allergy, and parasites infection. While M2b macrophages participate in the T-cell responses 
2 (Th2) responses and immunoregulation, IL10-stimulated M2c macrophages are mainly 
involved in inhibiting immune responses and tissue remodeling [31, 32]. 
 
1.1.3 Role of macrophages in obesity and T2D  
 
Obesity and its related metabolic disorders such as type 2 diabetes (T2D), liver and 
cardiovascular diseases are becoming worldwide problems in both developed and 
developing countries. Longtime sedentary lifestyles and Western diets can be associated 
with the global epidemic of those obesity-related metabolic diseases [33]. Insulin resistance 
is the principal mechanism that is involved in the pathogenesis of T2D. Unlike the classical 
acute inflammation, obesity induces a sustained low-grade chronic inflammation, also 
referred to metaflammation, which contributes to a series of following pathological changes 
[34]. In particular, obesity is thought to create a hyperlipidemic ‘metabolic stress’ 
microenvironment that induces inflammation in adipocytes. The critical involvement of 
macrophages in metaflammation is supported by several early clinical studies, which 
showed a strong correlation between macrophage infiltration in the adipose tissue of obese 
patients and the disease development [34]. In addition, ablation of macrophages or 
macrophage-derived key pro-inflammatory cytokines and chemokines significantly restore 
disease progression in obese mice models [35-38]. 
 
Insulin resistance reflects early glucose dysregulation in obesity. With the blunted insulin 
signaling pathways in the peripheral tissues such as adipose tissues, muscle, and liver, the 
uptake of glucose into those tissues is halted [39]. As a result, pancreatic b-cells need to 
produce sufficiently more insulin to antagonize this pathological change, overloaded of the 
pancreatic b-cells leads to cell death, followed by dropping of insulin secretion which leads 
to hyperglycemia and T2D [40]. Evidence shows that chronic tissue inflammation can lead 
to obesity-related insulin resistance. Obesity induces an insulin resistance state in these 
above tissues through a group of endocrine signaling pathway cross-talk [39]. 
 
 6 
Adipose tissue not only stores excess energy but also secretes fatty acids and adipokines 
including leptin, adiponectin, visfatin, vaspin, retinol-binding protein 4 (RBP4) and 
fibroblast growth factor 21 (FGF21) [41, 42]. Leptin, adiponectin, vaspin, and FGF21 
promote while RBP4 impairs insulin sensitivity [43-45]. During the obesity process, the 
adipose tissue is infiltrated with bone marrow-derived macrophages (BMDMs), which is 
the primary reason for chronic tissue inflammation [39, 46]. 
Obesity induces macrophage infiltration in different tissues including adipose tissue, 
muscle, liver, and brain along with increased levels of cytokines and chemokines (Figure 4) 
[47]. The hyper-nutrient microenvironment activates the abundantly recruited resident 
macrophages in insulin-sensitive tissues such as liver, adipose tissue, and muscle, thereby 
contributing to the chronic inflammation and metabolic dysregulation. The unique 
metabolically-activated inflammatory (metaflammatory) macrophage subtypes express 
cytokines like TNFa, inducible nitric oxide synthase (iNOS) and some chemokines like 
Figure 4. Macrophage infiltration in tissues during obesity.  
 
Reprinted from Nature Medicine, Vol. 18. p.363-374, Olivia Osborn and Jerrold M Olefsky. The cellular and 
signaling networks linking the immune system and metabolism in disease. doi:10.1038/nm.2627, Copyright 2012, 
with permission from Springer Nature. 
 
  7 
CCL2, CCL7 [40, 47].  
 
Interestingly, CCL2 seems to have a particular role in inducing local macrophage 
proliferation, leading to increased macrophage accumulation characterized as crown-like 
structures (CLS) in adipose tissues. In contrast to acute inflammation, where macrophages 
or monocytes are activated by endotoxins (LPS), the hyperlipidemia condition in obesity is 
also able to activate macrophages via interacting with the TLR2/4 receptors, thereby 
transcriptionally inducing gene expression of the above pro-inflammatory cytokines and 
chemokines [48].  
 
1.2 Transcriptional regulation in macrophages 
1.2.1 Mechanisms, transcription factors, and co-regulators  
   
Groups of stimulus-responsive TFs (SRTFs) such as nuclear factor kappa B (NF-kB) and 
lineage-determining TFs (LDTFs) such as PU.1 are involved in macrophage polarization 
(Figure 5) [8, 49, 50]. In IFNg-induced M1 macrophages, IFNg binds to IFNg receptor 
Figure 5. Transcription factor regulation in macrophage polarization.  
 
Reprinted from Nature Reviews Immunology, Vol. 11, p.750-761, Toby Lawrence and Gioacchino Natoli. 
Transcriptional regulation of macrophage polarization: enabling diversity with identity, doi:10.1038/nri3088, 
Copyright 2011, with permission from Springer Nature. 
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(IFNgR) and active signal transducer and activator of transcription 1 (STAT1) and 2 
(STAT2), which are the main TFs for M1 polarization [51]. In TLR4-activated M1 
macrophages, the ligand (LPS) binds to TLR4 and activate activator protein 1 (AP1) and 
NF-kB, which are dependent on myeloid differentiation primary response 88 (MYD88). 
Interferon regulatory factor 3 (IRF3)-medicated IFN-b expression is a TRIF-dependent 
pathway in LPS induced M1 macrophages [52]. CAMP-responsive element-binding protein 
(CREB), as a ZIP family TF, is involved in M2 polarization. LPS can activate CREB-
C/EBPb pathway to induce M2b macrophage through the immune response. In the M2b 
process, the M2 classic genes are inhibited by LPS while the LPS-mediated inflammatory 
genes are unaffected. The M2b-mediated CREB-C/EBPb pathway is crucial for wound 
healing [49, 53]. In the IL4/IL13-mediated M2 process, STAT6 is critical for the gene 
activation [49].  
Transcriptional regulation in macrophage activation is dynamic. One example is LPS 
(endotoxin) tolerance which represents a gene-selective LPS resistance status upon a 
second wave of stimulation after a chronic first wave of LPS treatment. Genes such as Tnfa 
and Il6 are still responsive to the second wave of LPS stimulation while others such as Ccl2 
and Ccl7 can no longer be induced by LPS. The physiological function of LPS tolerance is 
to decrease the excessive inflammatory response and allow the immune system to remain 
active. The endotoxin tolerance process can be divided into three stages involving different 
TFs. In the early stage, LPS rapidly induces primary response genes such as Tnfa through 
NF-κB and IRFs. In the second stage, LPS activates TFs such as C/EBPd. In the third stage, 
LPS induces a few TFs including PU.1, C/EBPb, RUNX1, and IRF8, which play roles in 
Figure 6. LPS /TLR4 signaling in macrophages.  
 
Reprinted from Nature Reviews Immunology, Vol. 11, p.692-703, Ruslan Medzhitov and Tiffany Horng. 
Transcriptional control of the inflammatory response, doi: 10.1038/nri2634, Copyright 2009, with permission from 
Nature. 
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the macrophage differentiation (Figure 6) [50].  These three stages are not independent but 
are functionally integrated within the transcriptional process. 
 
Beyond the key inflammatory TFs (PU.1, NF-kB, AP1, IRFs), several nuclear receptors 
(LXRs, PPARs), transcriptional co-regulators (co-activators, co-repressors), and kinases 
including c-Jun N-terminal kinases (JNK) and the IκB kinase (IKK) are involved in M1 
macrophage activation [34, 54].  The peroxisome proliferator-activated receptors (PPARs) 
are a group of metabolism-associated nuclear receptors. There are three isoforms of PPARs, 
namely PPARα, PPARβ/δ, and PPARγ, which are encoded by distinct genes and which are 
abundantly expressed in multiple metabolic tissues including macrophages. PPARs are 
reported to be involved in fatty acid metabolism; however, PPARs can also influence 
inflammation and immunity in macrophages. Activated PPARs can repress inflammatory 
genes such as Ccl2, Il6 in the presence of ligand.  PPARs regulate transcription via 
heterodimerizing with RXRs upon ligand stimulation. Up to now, synthesized ligands 
targeting PPARα (fibrates) and PPARγ (T2Ds) have been clinically applied for lipid-
lowering and insulin-sensitizing purposes [55, 56].  
 
The liver X receptor LXRα is highly expressed in liver, kidney, macrophages, lung, spleen, 
intestine, brain and adipose tissues, while LXRβ is expressed in almost all tissues and 
organs. The natural ligands for LXRs are oxysterols, oxygenated cholesterol, and 
cholestenoic acid. Synthetic agonists such as T0901317 and GW3965 were later developed 
for pharmacological studies. After ligand binding, LXRs bind to LXR response elements 
(LXRE), and activate LXR target gene transcription. LXRs are involved in lipid and 
cholesterol metabolism in macrophages. Activation of LXRs in macrophages leads to the 
transcription of several genes that are involved in lipid metabolism and reverse cholesterol 
transport such as Abca1 and Abcg1 [57-59].  
 
Depletion of nuclear receptor co-repressor 1(NCOR) in macrophages is associated with 
LXR activation linked with altered omega-3(w-3) fatty acid metabolism and improved 
metabolic phenotypes in a mouse model of diet-induced obesity [60]. Unlike PPARγ, which 
is rapidly downregulated upon inflammatory stimuli (e.g. LPS, unpublished data), both 
LXRα and β remain expressed during inflammation, potentially indicating LXRs as more 
potent drug targets for therapeutic intervention. LXRα is additionally involved in defining 
splenic macrophage specification [61]. LXR activation was reported to repress LPS-
 10 
induced inflammatory gene transcription via trans-repression, i.e. through inhibition of 
inflammatory TFs such as NF-kB [62, 63].  
 
Last but not least, so-called co-regulators are crucial components of transcriptional 
regulation in macrophages. Co-regulators interact with and modulate the activity of TFs, 
and they function within larger multiprotein complexes to modify chromatin states linked to 
transcriptional activity. Inflammatory gene expression requires co-activator complexes 
possessing histone acetylase (HAT) activities, formed by CREB-binding protein (CBP) and 
the related E1A binding protein p300 (p300) to remodel nucleosome activity [64, 65]. In 
contrast, multiple co-repressor complexes, including those possessing histone de-acetylase 
(HDAC) activities, are required to maintain repressed states and to silence gene expression 
upon activation (feedback control) in macrophages [65, 66]. 
1.2.2 The GPS2 subunit of the HDAC3 co-repressor complex 
   
Co-repressor complexes formed by NCOR and the related silencing mediator of retinoic-
acid and thyroid-hormone receptor (SMRT) were discovered in 2000 by different groups 
[67-69]. The NCOR/SMRT complex contains transducin b-like 1 (TBL1), TBL1-related 
Figure 7. HDAC3 co-repressor complex in control of inflammatory gene transcription.  
 
Reprinted from Nature Reviews Immunology, Vol 6, p.44-55, Christopher K. Glass and Sumito Ogawa. 
Combinatorial roles of nuclear receptors in inflammation and immunity, doi: 10.1038/nri1748, Copyright 2006, with 
permission from Springer Nature. 
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protein (TBLR1), G-protein pathway suppressor 2 (GPS2) and histone deacetylase 3 
(HDAC3). These core subunits interact with each other and assemble into a main co-
repressor complex to inhibit gene transcription in macrophages and other cell types. When 
cells are exposed to a particular stimulus such as pro-inflammatory cytokines, the HDAC3 
complex releases, allowing co-activators to bind and to stimulate transcription (Figure 7) 
[65]. 
 
NCOR (also known as N-CoR, NCOR1) is a corepressor of a broad range of TFs. It is a 
large protein of approximately 270 kDa and it is expressed seemingly ubiquitously, i.e. in 
all tissues. NCOR contains two distinct C-terminal domains that are required for 
interactions with nuclear receptors [70], while interactions with multiple TFs require other 
domains. SMRT (also known as NCOR2, nuclear receptor co-repressor 2) is a NCOR 
related factor that was discovered in 1995 [71]. SMRT and NCOR share similar structures 
and have conserved functional domains, which allows them acting in part redundant. 
 
Histone deacetylases (HDACs) are a group of proteins that regulate histone and non-histone 
protein acetylation and deacetylation [72]. The HDAC superfamily is classified into four 
classes depending on sequence homology. HDAC1, HDAC2, HDAC3, and HDAC8 belong 
to class I. HDAC3 is ubiquitously expressed and the major enzymatic component of the 
NCOR/SMRT co-repressor complex [73]. 
 
GPS2 (also named AMF1) was initially identified in genetic screens for suppressors of G-
protein mutations in Saccharomyces cerevisiae [74]. GPS2 is a highly conserved 37 kDa 
protein, containing 327 amino acid residues in mice and humans, which is expressed in 
most tissues. GPS2 was also found to interact with virus proteins such as human 
papillomavirus (HPV), bovine papillomavirus type 1 (BPV-1) and Hepatitis C virus (HCV) 
[75, 76]. The transcriptional functions of GPS2 started to become evident when it was 
subsequently identified as a subunit of the HDAC3 co-repressor complex [77]. 
Interestingly, GPS2 could inhibit TNFα-induced JNK activation, thus discovering the first 
link to inflammatory pathways [78]. Other studies revealed that GPS2 also can influence c-
Jun, p53, and p300 activities and thereby regulate the transcription of inflammatory and 
cancer-related genes [79, 80]. Studies by the Treuter laboratory identified GPS2 as a 
significant regulator in bile acid biosynthesis: In human hepatocyte cell lines, GPS2 
regulates cytochrome P450 7A1 (CYP7A1) and cytochrome P450 8B1(CYP8B1) expression 
which are the two major enzymes in bile acid pathway [81]. Later on, Jakobsson et al. 
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reported that in human hepatocytes and macrophages GPS2 was required for the LXR-
dependent expression of ABCG1, a major cholesterol transporter in macrophages [82]. 
Zhang et al. also showed that GPS2 interacts with Regulatory Factor X4 Variant 3 
(RFX4v3) and trans-activates CX3C-type chemokine gene expression [83]. These few 
studies indicated that GPS2 does in certain contexts also work as a ‘co-activator’ in 
macrophages.  
 
There is growing evidence that altered expression and function of subunits of the HDAC3 
co-repressor complex associates with certain cancers and metabolic diseases. Research 
uncovered the reduced expression of NCOR in breast and bladder cancers cell lines [84, 85] 
and in vivo experiments showed NCOR function as an oncogene through transcriptional 
regulation [86]. GPS2 expression was down-regulated in liposarcoma, and depletion of 
GPS2 in vitro in a liposarcoma cell line increased proliferation and migration [87], 
suggesting GPS2 to act as a tumor suppressor in liposarcoma. TBL1 was reported as a 
tumor suppressor gene in pancreatic cancer cells by controlling cell proliferation and 
invasion [88]. TBL1 was further implicated in controlling liver steatosis in metabolic 
syndrome patients [89]. The related TBLR1 acts as a co-activator to repress prostate cancer 
proliferation via the androgen receptor (AR) [90]. Jiao et al. reported that HDAC3 was 
upregulated in human pancreatic cancer and depletion of HDAC3 decreased the cell 
proliferation in vitro [91].  
 
Low-grade chronic inflammation can cause adipose tissue dysfunction and is a major 
characteristic and risk factor of obesity. Toubal et al. reported that GPS2 and SMRT were 
significantly reduced in adipose tissue of obese humans, as compared to non-obese, and this 
was inversely correlated to the state of metaflammation (i.e. macrophage infiltration in the 
adipose tissue, systemic inflammation, insulin resistance). After gastric bypass surgery, the 
patients´ inflammatory status was improved along with a restored expression of GPS2 and 
SMRT, suggesting a causal relationship [92].  The key inflammatory mediators in adipose 
tissue, such as CCL2, IL6, and IL8, and the regulation by the NCOR co-repressor complex 
are considered to be particularly critical for obesity development. These findings point at a 
particular function of the HDAC3 co-repressor complex in obesity and suggest that 
alterations of epigenetic regulatory networks potentially underly the chronic inflammatory 
status of obese adipose tissue [92]. 
1.2.3 Knockout mouse models for HDAC3 co-repressor complex subunits 
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Although the co-repressor complex subunits are assumed to physiologically function 
together, the reported knockout mouse models for NCOR, HDAC3 and TBLR1 display 
different phenotypes (Table 1). Adipocyte-specific TBLR1 knockout mice result in obesity 
and metabolic dysfunction through reduced lipolysis [93]. Surprisingly, NCOR knockout 
mice in both adipocytes and macrophages display anti-inflammatory phenotypes [60, 94]. 
High-fat diet (HFD) induced insulin sensitivity, improved glucose levels, and reduced 
inflammation. The NCOR knockout phenotype in adipocytes may be due to up-regulated 
PPARγ target genes and enhanced insulin sensitivity by increased cyclin-dependent kinase 
5 (CDK5)-mediated PPARγ phosphorylation [94]. In contrast, the NCOR knockout 
phenotype in macrophages may be due to elevated LXR-dependent w3-fatty acids gene 
expression, which subsequently caused inflammatory gene repression [60]. 
 
Table 1 Knockout mouse models for subunits of the HDAC3 co-repressor complex. 
Protein Mouse model Phenotypes High-fat diet 
(HFD) 
Mechanism 
SMRT Macrophage knockout - - - 
 Adipocyte knockout - - - 
NCOR Macrophage knockout Anti-inflammatory  Reduced 
inflammation, 
improve 
glucose 
tolerance, 
enhance insulin 
sensitivity 
De-repression of 
LXR-mediated w3- 
fatty acid synthesis 
[60] 
 Adipocyte knockout Anti-inflammatory  Increased 
obesity, 
improve 
glucose 
tolerance, 
enhance insulin 
sensitivity 
Changes in PPARg 
phosphorylation [94] 
HDAC3 Macrophage knockout Anti-inflammatory  - Epigenetic 
modifications such 
as histone 
acetylation activity 
changes [95, 96] 
 Adipocyte knockout 
 
 
Adipocyte knockout 
Lethal [97] 
 
 
Enhanced browning of 
white adipose tissue 
- 
 
 
No effect  
- 
 
 
Activation of de 
novo fatty acid 
synthesis and β-
oxidation [98] 
TBLR1 Macrophage knockout - - - 
 Adipocyte knockout Pro-inflammatory [93] Aggravated 
adiposity, 
insulin 
resistance, 
glucose 
intolerance 
- 
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Macrophages were unable to induce many inflammatory genes expression such as Il6, 
Ptgs2, Tnfα upon knockout of HDAC3 [95], which increased Cox1 expression and inhibited 
basal and LPS-induced Ifnb1 gene expression that could impair the secondary response to 
LPS. On the other hand, it was reported that HDAC3 functions as an epigenomic brake in 
alternative M2 macrophage activation. When exposed to IL4/IL13, HDAC3-deficient 
macrophages had elevated M2 marker gene expression [96]. HDAC3 knockout in white 
adipose tissue was lethal by using fatty acid binding protein 4 (Fabp4)-Cre mice, which the 
indicates the crucial roles of HDAC3 in adipose physiology [97]. However, another group 
reported the HDAC3 knockout using adiponectin-Cre mice regulated the white adipose 
tissue metabolism and function [98]. 
1.3 Enhancers - key elements of the macrophage epigenome 
1.3.1    Enhancer structure and function relationship 
 
The term ‘enhancer’ was first coined in studies using simian virus 40 (SV40) over 30 years 
ago [99]. Schaffner described that a 72-bp SV40 element could increase the expression of 
the rabbit β-globin gene in HeLa cells and further studies showed that this element could 
enhance transcription in many other promoter contexts [99, 100]. Since then, an enhancer is 
defined as a cis-regulatory DNA element which can independently activate the downstream 
gene transcription from a distance. Such regulatory elements contain specific recognition 
sequences for multiple TFs that enables precise spatiotemporal patterns of gene expression 
during development and cellular response to stimuli. Enhancers positively regulate the 
transcription activity of promoters and are thus critical for gene expression. Deleting 
enhancers can affect histone modifications and loop-mediated chromatin structures [101, 
102].  
 
High-throughput DNA sequencing techniques such as ChIP-sequencing (ChIP-seq) and 
DNase I hypersensitive sites sequencing (DNase-seq) enabled researchers to discover 
enhancers in a genome-wide scale [103-106]. The histone modifications H3K27ac and 
H3K4me1 are usually used as enhancer markers and some LDTFs such as sex determining 
region Y-box 2 (SOX2) and octamer-binding transcription factor 4 (OCT4) and mediator 
(e.g. MED1) were also reported as enhancer markers in specific cell types [101, 107, 108]. 
Thus, the recruitment of these factors along with specific histone markers can be used to 
map and evaluate enhancer activities. 
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The general regulatory functions of enhancers are mediated through several mechanisms. 1) 
Recruiting and releasing of enhancer-regulating TFs. For example, estrogen receptors (ERs), 
forkhead box protein A1 (FOXA1), LXR, and PU.1 bind to enhancers and promoters are 
dependent on the DNA-binding motifs [82, 109-111], which causes the transcription of 
target genes. 2) Transcriptional output via enhancer-derived non-coding RNAs (eRNAs). 
The transcription on the enhancer itself can affect the enhancer and promoter 
communication. There is evidence suggesting that eRNAs are functionally required for 
gene transcription and not just transcription noise or non-functional byproducts of enhancer 
transcription [112-114]. 3) Maintenance of enhancer-promoter looping structures. 
enhancer-promoter loops are another critical mechanism for gene inter-regulation. Genome-
wide enhancer-promoter interactions (by Hi-C) and individual genes loop formation (by 3C 
and modified 4C, 5C) are primarily studied [115-117], showing that loop formations are 
common events in nuclear chromatin/DNA organization. 
 
Compare to typical enhancers, super-enhancers tend to span larger genomic regions of high 
chromatin accessibility, which enrich RNA polymerase II (Pol II), MED1, bromodomain 
containing 4 (BRD4), eRNAs, p300, CCCTC-Binding Factor (CTCF)/cohesin, H3K27ac, 
H3K4me2, and H3K4me1 [118]. Super-enhancers are cell type-specific and often found in 
the genes which have cell type-specific functions. In cancer cells, super-enhancers are 
enriched at oncogenes such as MYC proto-oncogene (MYC) [108, 119, 120]. In embryonic 
development, super-enhancers are assembled by the stem cell TFs such as Oct4, Sox2, 
kruppel-like factor 4 (Klf4), and homeobox transcription factor nanog (Nanog) [107].   
 
The well-explained mechanisms for the regulation of enhancers on target genes are 
enhancer-promoter communication, which requires the formation of 3D chromatin looping 
structures [116]. Generally, the enhancer-promoter loop formation is required by the 
enhancer, cohesin-loading factor, DNA binding proteins, and other transcription machinery 
proteins such as Pol II and promoter. Nowadays, the loop-mediated gene regulation is 
commonly accepted while the emerging evidence shows the eRNAs are crucial for loop 
formation and gene expression [121]. 
 
Macrophage activation is also largely dependent on enhancers. According to mouse studies, 
there are about 1800 macrophage-specific genes along with 4700 macrophage-specific 
enhancers [122]. In response to stimuli such as LPS and IFNg, macrophage gene activation 
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is profoundly marked by histone H3K4me1, H3K4me2, low enrichment by H3K4me3, and 
are controlled by the LDTF PU.1, C/EBP, AP1 [101, 111].  Notably, in both M1 and M2 
activation, macrophage de novo enhancers (latent enhancers) play a central role in gene 
expression. In M1 activation, some pre-existing enhancers marked by H3K4me1, 
H3K4me2, H3K27ac, and PU.1 can loose, and others can gain function [111, 123]. In M2 
activation, about 260 active enhancers control 314 responsive genes [122]. Pol II 
transcription which overlapped with the histone markers are principally enriched in 
macrophage activation, and global analysis shows the enhancer activities are correlated 
with eRNA transcription linked with nearby gene expression [124]. 
 
Functional genomic studies have shown that super-enhancers are required for gene 
expression, cell identities, tumor pathogenesis, and cell development. For example, super-
enhancers can be used as biomarkers for tumor-specific pathologies [119]. Graham et al. 
also showed that the nuclear receptor subfamily 4 group A member 1 (Nr4a1) enhancer 
deletion could affect the development of Ly6Clow monocytes with minor effects on 
inflammation [125]. Krüppel-like factor 2 (KLF2) specifically binds to the target enhancer 
regions and controls monocyte differentiation [125]. Another study has demonstrated that 
deletion of a MYC oncogene core enhancer in mice resulted in resistance to intestinal 
tumorigenesis while not leading to global MYC inactivation, indicating cell specificity of 
enhancers [126]. Moreover, Xiao et al. demonstrated super-enhancer medicated Il9 
expression in T helper type 9 (Th9) cells in airway inflammation, which provides 
therapeutic potential for clinical applications [127].  
 
Overall, while there are more than 150,000 enhancers in human and mouse cells, only a few 
enhancers have been functionally tested so far. Therefore, our current understanding of 
enhancer function in mammalian cells, including macrophages, is limited. For example, it is 
currently very difficult to predict how many functional enhancers control a given gene, how 
many genes are controlled by a given enhancer, and how diverse inflammatory signals 
control individual enhancers and linked genes. 
1.3.2 Role of enhancer-transcribed eRNAs 
 
While only 1% of the human genome consists of protein-coding genes, numerous studies 
have recently uncovered that more than 60% is transcribed into diverse non-coding RNAs 
[105]. eRNAs are non-coding transcripts that originate from H3K27ac-, H3K4me2- and 
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H3K4me1-marked enhancer regions. eRNAs are less than 2000 bp in length and usually do 
not have splice variants.  Consistent with their origin, the expression of many eRNAs is 
highly tissue-specific and poorly conserved between species. Non-polyadenylated eRNAs 
are much more frequent than polyadenylated eRNAs [128-130]. Caused by the lack of 
polyadenylation and termination sites, eRNAs can be easily degraded by exosomes [129].  
 
Enhancer transcription involves two main steps, i.e. the enhancer priming, and enhancer 
transcription initiation. In the first step, pioneer TFs, LDTFs, and co-regulators cooperate to 
open chromatin and modulate histones at enhancers. In the second step, additional key TFs 
including SRTFs, CBP/p300, MED1, and Pol II are recruited to initiate transcription [128]. 
As with messenger RNA (mRNA) transcription, eRNAs may be additionally controlled at 
the level of elongation.  
 
Due to the low abundance and easy-to-degrade characteristics of eRNAs, detection of 
eRNA remained technically challenging. In addition, as most of eRNAs lack polyA, the 
polyA-based RNA-sequencing (RNA-seq) is not suitable for detecting eRNAs. Reverse 
transcription-PCR (RT-PCR) can be used for the eRNA detection when using random 
primers [131]. Global run-on sequencing (GRO-seq) and its improved versions is a robust 
method to identify eRNAs [113, 132, 133].  RNA fluorescence in situ hybridization (RNA-
FISH) is a DNA probe-based method to ascertain the localization of individual eRNAs [134, 
135]. Pol II ChIP-seq provides indirect evidence to show the correlation between the target 
genomic region and the transcription products [124, 131]. 
 
How exactly eRNAs regulate transcription is not yet understood. However, eRNAs share 
common features with other types of long non-coding RNAs (lncRNAs) which may help to 
propose mechanisms of eRNA function (Figure 8) [130]. There are currently at least three 
models to explain the transcriptional regulatory mechanisms of lncRNAs. The first model is 
that the lncRNA can recruit the transcription machinery to target gene promoters. For 
example, the steroid receptor RNA activator (SRA), HOXA transcript at the distal tip 
(HOTTIP), Miranda (Mira) and distal-less homeobox 6 antisense RNA 1(DLX6-AS1) were 
reported to recruit TFs and activators to enhance transcription [136-139]. The second model 
is that lncRNAs facilitate enhancer-promoter loop formation [140]. The third model is that 
lncRNAs such as Braveheart [141] can activate target gene expression by promoting the 
release of co-repressors. 
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A few studies suggest that lnc/eRNAs play crucial roles in macrophage differentiation and 
stimulus-response [142].  The lincR-Ccr2-5´AS expression can regulate the Th2 related 
inflammatory gene expression. The ncRNA THRIL recruits ribonucleoprotein L (RNPL) to 
enhancers to control TNFa expression [143]. Xiao et al. reported that the IL9 super-
enhancer and its related eRNA control airway inflammation [127]. 
Despite numerous studies which support the functionality of eRNAs, the relevance and 
implications are currently debated and there is no final consensus as to the mechanisms of 
eRNA regulation and function. One challenging part is that eRNAs are expressed at low 
levels and unstable, and most of them are expressed only in the nucleus, which make 
approaches to degrade eRNAs via RNA interference (RNAi) not suitable [144-146]. Using 
a polyadenylation signal to terminate eRNA expression will perhaps provide an alternative 
Figure 8. Models of lncRNA function that may apply to eRNAs. 
 
Reprinted from Trends in Biochemical Science, Vol 39. p.170-182, Michael T.Y. Lam et al., Enhancer RNAs and 
regulated transcriptional programs. doi: 10.1016/j.tibs.2014.02.007, Copyright 2014, with permission from Elsevier. 
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way to interfere with eRNA function [147, 148]. Related inhibitory experiments that 
specifically target the eRNA and not the process of enhancer transcription would be needed 
to test for function. Until then, the key argument that enhancer transcription is non-
functional ‘noise’, i.e. a byproduct of Pol II at open enhancer chromatin, cannot be 
dismissed [121, 149]. 
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2 OBJECTIVES AND AIMS  
 
2.1     General Objective 
 
The objective of this thesis is to characterize the functions of the anti-inflammatory co-
regulator protein GPS2, and of GPS2-containing multi-protein complexes, at the molecular 
and physiological level. Particular emphasis will be on dissecting transcriptional pathways 
and epigenome alterations in macrophages that potentially link GPS2 to metabolic-
inflammatory diseases.  
 
2.2     Specific Aims 
 
1) To determine the role of GPS2 in RCT in macrophages. Focus on characterizing 
metabolic and inflammatory signals, key target genes and key TFs as well as the role of 
other corepressor complex subunits. 
 
2) To investigate how the GPS2-containing co-repressor complex regulates pro-
inflammatory macrophage enhancers linked to genes of significance for the development 
of obesity-linked T2D. Focus on enhancers and eRNAs potentially controlling the 
expression of the chemokine Ccl2, a major GPS2 target in adipose tissue-macrophages.  
 
3) To generate and characterize macrophage-specific Gps2 knockout mice and cell lines. 
Focus on integrative physiology and epigenomics, i.e. studying the causal relationship 
between loss-of-GPS2, epigenome alterations and phenotypes potentially linked to 
metaflammatory diseases. 
 
4) To characterize liver-specific Gps2 knockout mice. Focus on the consequences of GPS2 
depletion on lipid metabolism and on the development of obesity-induced non-alcoholic 
fatty liver disease (NAFLD). 
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3 METHODOLOGICAL CONSIDERATIONS  
 
A detailed description of all experimental and computational methods used in the thesis are 
provided in the individual publications or manuscripts. The goal of this section is to discuss 
the advantages and disadvantages of key methods.  
 
3.1    Mouse models and primary macrophages 
 
In all studies, we used macrophage-specific Gps2 knockout mice, along with wild-type 
(floxed) mice, in the C57B1/6J background to investigate GPS2 functions in inflammation 
and metabolism [150]. We isolated primary mouse bone marrow-derived macrophages 
(BMDMs) and mouse thioglycollate-elicited peritoneal macrophages (TEPMs) and used 
LPS to induce macrophage M1 inflammation response [150-152]. 
3.2    Macrophage cell lines 
 
The main macrophage cell line used in this study was RAW 264.7, which was purchased 
from the American Type Culture Collection (ATCC, TIB-71). The human macrophage cell 
line THP1 (ATCC, TIB-202) was additionally used in Paper I. Both RAW264.7 and THP1 
cells are important and widely used in vitro tools for immunology research. RAW264.7 is a 
macrophage-like cell line, which originated from a leukemia mouse in 1978. Compared to 
primary mouse-derived BMDMs and TEPMs, the RAW264.7 cell line has similar genomic 
structure, gene expression patterns and immune responses and can be easily cultured in 
vitro, use serving a relevant alternative in vitro model in line with the 3R-principle. 
 
3.3 CRISPR/Cas9-based gene editing  
 
The clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing 
technology was used in this thesis to delete non-coding (e.g. enhancers, promoters) and 
coding (e.g. Gps2) DNA sequences in RAW 264.7 cells. CRISPR and its related genes are 
essential for adaptive immunity in bacteria, enabling the organisms to eliminate invading 
genetic changes [153]. We further used modifications referred to as CRISPRi/dCas9 to 
disturb transcription without DNA editing [154-156]. 
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3.4 Adenovirus and lentivirus-mediated RNAi knockdown 
 
In order to silence gene expression via knockdown of a particular mRNA in vitro, RNAi 
using short hairpin RNAs (shRNA) is used in this thesis. Basically, shRNAs are artificial 
RNAs that have a hairpin turn, which is degraded in a process catalyzed by the Dicer 
enzyme. This process will cause the RNA-induced silencing complex (RISC) to bind to the 
target mRNA and cause subsequent degradation. Both adenovirus and lentivirus were used 
to deliver the shRNAs. Because macrophages have low transfection rates using 
conventional small interfering RNAs (siRNA), the virus-based shRNAs provide potent 
alternatives to silence gene expression in macrophages. Through the Paper I and Paper II 
we mainly used lentivirus to knockdown particular genes via generating stable cell lines.  
 
3.5 Chromatin immunoprecipitation-coupled sequencing (ChIP-seq) 
 
ChIP-seq is a powerful tool to investigate the genome-wide binding profile of a particular 
TF, co-regulator or epigenetic histone mark such as H3K27ac and H3K4me3. Despite there 
are many in part distinct experimental procedures, high-quality ChIP-seq data are largely 
dependent on the quality of the antibody and the crosslinking and sonication conditions 
which can differ amongst cell-types and targets. Antibody quality is the most critical issue 
for ChIP-seq.  In this thesis, we performed ChIP-seq for GPS2 (using self-made custom 
rabbit polyclonal antibodies raised against N- and C-terminal GPS2 epitopes), H3K27ac 
and H3K4me3 in RAW264.7 cells. 
 
3.6 RNA sequencing (RNA-seq, GRO-seq) 
 
Next-generation sequencing (NGS) technologies have revolutionized the genome-wide 
analysis of transcriptomes via RNA-seq. RNA-seq identifies globally differential 
expression of both known and unknown genes and non-coding RNAs, which cannot be 
detected using probe-based microarray methods. RNA-seq is usually a Pol II-based method, 
which will involve a poly(A)-mRNA selection step [157]. In this thesis, we used Illumina 
HiSeq 2000 for global transcriptome sequencing.  
Global run-on sequencing (GRO-seq) is another high-throughput sequencing method which 
detects nascent RNAs, both coding pre-mRNAs and different classes of ncRNAs including 
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eRNAs [111, 158]. In this thesis, we have established and applied GRO-seq in RAW264.7 
cells and BMDMs (in collaboration with Dr. Minna Kaikkonen, Kuopio University). 
 
3.7 Cholesterol efflux assay 
 
Macrophages play a critical role in RCT by transporting intra-cellular cholesterol to plasma 
in the form of HDL. ABCA1 and ABCG1 are the major macrophage cholesterol 
transporters in mice and humans, the expression of which is regulated by oxysterols (via 
LXRs) and inflammatory signals (likely via inflammatory TFs, to be characterized). The 
cholesterol efflux assay is used to test the capacity of cells to export cholesterol.  In this 
thesis, we used a fluorescence-based cholesterol efflux assay to examine the influences of 
GPS2 on cholesterol transportation. Comparing to the typical [3H] cholesterol based 
method; the fluorescence method is non-radioactive and high-throughput. 
 
3.8 Locked Nucleic Acids (LNA)-based eRNA depletion 
 
Although small interfering RNAs (siRNA) are widely used to degrade mRNAs via RNase 
A in the cytoplasm, they cannot be used to degrade nuclear-localized ncRNAs including 
eRNAs. This can be achieved via antisense Locked Nucleic Acids (LNA), which are 
modified RNAs, both in vitro and in vivo. In this thesis, we used antisense LNAs (obtained 
from Exiqon/Qiagen) to degrade different Ccl2 enhancer eRNAs. 
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4  RESULTS AND DISCUSSION  
4.1     Paper I: GPS2 is required for LPS-induced cholesterol efflux 
 
To investigate GPS2 role in macrophages metabolism, we used both CRISPR/Cas9 GPS2 
knockout and lentivirus GPS2 knockdown systems in RAW264.7 cells. We observed that 
GPS2 depletion caused significant down-regulation of Abca1, a main cholesterol 
transporter gene in macrophages, along with up-regulation of chemoattractant genes Ccl2 
and Ccl7, upon LPS treatment. Further experiments revealed that GPS2 depletion 
significantly decreased LPS-mediated cholesterol efflux. Unlike the classic ABCA1 
induction by LXR agonists, induction by LPS involved the TLR4/p65 signaling pathway. 
GPS2 depletion had only minor effects on LXR agonist-induced Abca1 expression, which 
suggests GPS2 to act independently of LXR. However, GPS2 depletion resulted in the loss 
of LXR trans-repression, as shown for Ccl7. Double knockdown of GPS2 and p65 
experiments showed that the expression of Abca1 was not further inhibited by depletion of 
p65 in GPS2-depleted RAW cells. These data suggest that GPS2 cooperates with p65 but 
not with LXRs to induce Abca1 expression in response to LPS.  
  
While GPS2 mostly acts as a subunit of the HDAC3 co-repressor complex to repress target 
gene expression, our data further suggest that the activation of ABCA1 was independent of 
NCOR and SMRT, the major GPS2-binding subunits in the complex. However, HDAC3 
knockdown also abolished LPS-induced Abca1 expression, which may indicate a potential 
cooperation between GPS2 and HDAC3. 
 
We further dissected the genomic mechanisms behind the GPS2 regulation of Abca1 
expression using ChIP-seq. We compared the GPS2, LXR and p65 ChIP-seq data (i.e. the 
cistromes of these factors) at the Abca1 gene locus, which revealed co-occupancy of GPS2 
and p65 at Abca1 gene promoter and enhancers. In contrast, LXR binding was in part 
different from GPS2, consistent with the LXR-independence of the LPS/GPS2-regulated 
Abca1 expression. ChIP experiments at Abca1 promoter and enhancer further showed that 
depletion of GPS2 significantly decreased p65 binding upon LPS treatment, and depletion 
of p65 abolished GPS2 binding, which supports the physical interaction and dependence of 
the two factors (Figure 9).   
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We finally attempted to verify the key results in the human monocyte THP1 cell line. The 
data showed that knockdown of GPS2 also decreased LPS-induced ABCA1 expression 
while having a minor effect on LXR ligand-induced ABCA1expression. This result suggests 
that the ABCA1 gene regulation by GPS2 and LPS is conserved between humans and mice.  
4.2  Paper II: GPS2 represses macrophage enhancers and eRNA transcription 
 
In order to generate a cistrome profile of GPS2 binding in an in vitro macrophage system, 
we performed GPS2 ChIP-seq in the RAW264.7 cell line upon LPS treatment. Combining 
GPS2 depletion with RNA-seq transcriptome data, we found GPS2´s binding was enriched 
at promoters and enhancers to repress expression of inflammatory genes, including Ccl2 
and Ccl7. Upon removing GPS2, Ccl2 expression was upregulated along with a significant 
enrichment of the histone modification H3K27ac (an active histone/epigenome mark) at 
both Ccl2 promoter and enhancers. Kinetic binding analysis upon LPS treatment revealed 
GPS2 release and re-binding selectively at enhancers of a specific gene cluster (group 2). 
Notably, group 2 contains many of the top GPS2-repressed target genes. enriched in 
inflammatory chemokine signaling pathways according to Kyoto encyclopedia of genes and 
Figure 9.  Regulation of ABCA1-dependent cholesterol efflux by GPS2. 
 
Reprinted from The FASEB Journal, Zhiqiang Huang et al., G protein pathway suppressor 2 (GPS2) links 
inflammation and cholesterol efflux by controlling lipopolysaccharide-induced ATP-binding cassette transporter A1 
expression in macrophages. https://doi.org/10.1096/fj.201801123R, Copyright 2018. 
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genomes (KEGG) pathway analysis. Overall, these data revealed a correlation between 
GPS2 cistrome, epigenome, and transcriptome. 
 
To gain a better understanding of the detailed regulation of GPS2 on its target genes, we 
choose the most significant gene Ccl2 to investigate the underlying mechanisms. We 
compared the ChIP-seq data of the epigenetic histone marks H3K4me3 and H3K27ac with 
the GPS2 cistrome and found co-occupancy at several Ccl2 enhancers. To identify which of 
the GPS2-positive enhancers were functionally required for Ccl2 expression, we deleted the 
distal and proximal enhancers using CRISPR/Cas9. We found the distal enhancer E1 was 
crucial for Ccl2 expression, while the proximal enhancer E2 was dispensable, despite being 
marked by GPS2 and H3K27ac. GRO-seq data revealed that upon LPS treatment the 
enhancer E1 region produced eRNAs, which was repressed by GPS2. We further tested 
eRNA function of enhancer E1 using LNAs and CRISPR interference, which additionally 
revealed that eRNA transcription was not affected by promoter deletion. 
 
In sum, these data support the involvement of enhancer E1 eRNA transcription in 
controlling the LPS-inducible expression of Ccl2 and the adjacent co-regulated Ccl7 gene. 
They point further at a sequence of events during LPS-activation, starting with the release 
of the GPS2 complex (de-repression), eRNA synthesis, H3K27 acetylation, and mRNA 
synthesis. While Ccl2 mRNA synthesis depends on the presence of the Ccl2 promoter, 
synthesis of the Ccl2 eRNAs does not, indicating independent regulation of eRNA 
transcription. The conclusions of Paper III are summarized in a model (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.  Model of Ccl2 enhancer repression by GPS2. 
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4.3 Paper III: Loss of GPS2 triggers metaflammation in mice and human 
macrophages 
 
The correlation between GPS2, inflammation and T2D risk in human macrophages. 
 
In collaboration with Dr. Nicolas Venteclef (INSERM Paris), we investigated the 
expression of the genes encoding GPS2 and all other corepressor complex core subunits in 
obese/T2D human subjects from three distinct populations. In obese patients, GPS2 
expression in adipose tissue macrophages (ATMs) was negatively correlated with 
inflammatory status and T2D risk score. GPS2 overexpression in ATMs caused the 
repression of pro-inflammatory chemokine (CCL2) and cytokines including interleukin 1 
beta (IL1b), IL6, IL8, and TNFa) genes.  On the contrary, RNAi-mediated GPS2 depletion 
in ATMs upregulated theses inflammatory genes. Microarray data also showed that GPS2 
depletion in human monocyte-derived macrophages (HMDMs) displayed a pro-
inflammatory gene signature. These data suggested that GPS2 in human macrophages, 
particular in ATMs, could be causally related to inflammation and T2D. 
 
GPS2-deficient mouse macrophages display a pro-inflammatory gene signature and 
enhanced TLR activation upon infectious or metabolic signaling. 
 
Macrophage-specific GPS2 knockout (MKO) mice were generated and used to investigate 
GPS2-regulated transcriptomes in BMDMs and TEPMs from MKO versus WT mice using 
microarrays. We found at the genome-wide scale that the pro-inflammatory GPS2 gene 
signature, obtained from unstimulated BMDMs, substantially overlaps with the LPS/TLR4 
signature obtained from TEPMs. The microarray results additionally suggested that GPS2 
removal might affect the LPS responses in macrophages. 
 
To investigate whether and how the lack of GPS2 affects ATM function and gene 
expression in vivo under conditions of metaflammation, WT and MKO mice were subjected 
to 60% HFD feeding, compared to the low-fat diet (LFD) for 12 weeks. We found that 
removal of GPS2 from macrophages did not result in significant changes in body weight 
gain, and food and water intake (data not shown). Most strikingly, the infiltration of 
macrophages (F4/80+CD11b+ ATMs) was increased in MKO compared to WT mice 
within both epididymal white adipose tissue (epiWAT) and inguinal white adipose tissue 
(ingWAT), as visualized by immunohistochemistry (IHC) and quantified by flow cytometry. 
Importantly, analysis of Gps2 expression in epiWAT of WT mice subjected to control LFD 
 30 
versus HFD for 4, 8 and 12 weeks revealed a significant decrease of Gps2 mRNA levels. 
Therefore, the down-regulation of Gps2 levels in response to HFD might be a 
compensatory mechanism that limits the anti-inflammatory action of GPS2 in macrophages 
under conditions of obesity. 
 
The intersection of the GPS2 cistrome, epigenome, and transcriptome. 
 
In order to define the genomic DNA occupancy (the cistrome) of GPS2, in relation to the 
epigenetic landscape (the epigenome) and gene expression (the transcriptome), we 
performed ChIP-seq in BMDMs of GPS2 WT versus MKO mice. De novo motif analysis 
showed that GPS2-enriched regions were specifically bound for motifs recognized by 
LDTFs such as PU.1/ETS, C/EBP, and RUNX, which is consistent with the role of these 
factors in macrophages [159]. Amongst the motifs recognized by SDTFs, AP-1/ATF and 
IRF motifs were most abundantly enriched in GPS2-bound regions, suggesting the 
communication between GPS2 and these TFs to repress pro-inflammatory gene expression. 
Surprisingly, NF-kB motifs and nuclear receptor half-site motifs were only poorly enriched 
of the GPS-bound regions, raising questions about the importance of these TFs in 
communicating with GPS2 in macrophages, at least at the genome-wide level. The 
comparative analysis of changes in histone marks (epigenome) and transcriptome in MKO 
versus WT macrophages uncovered quantitative increases of H3K27ac and H3K4me3 
signal intensity at enhancers/promoters of pro-inflammatory signature genes that were up-
regulated upon GPS2-removal indicative of transcriptional de-repression/activation. As an 
example, in GPS2-deficient macrophages H3K27 acetylation increased by up to 69% and 
109% at the promoters of the ‘GPS2-sensitive’ Ccl2 and Ccl7 gene cluster respectively, and 
by 65% at the first Ccl2 enhancer E1, which was 35 kb upstream of transcription start site 
(TSS), and around 41% at the second Ccl2 enhancer E2, which was 15 kb upstream of TSS.  
 
Macrophage GPS2-deficiency causes enhanced pro-inflammatory gene expression in AT in 
response to HFD feeding.  
 
To test whether increased macrophage infiltration in MKO AT was likely a consequence of 
corresponding changes in gene expression, MKO versus WT mice were subjected to HFD 
feeding and analyzed by microarray and qRT-PCR. This was further substantiated by a 
kinetic qRT-PCR analysis of the HFD response in AT, demonstrating an elevated 
expression of GPS2 signature chemokines, such as Ccl2, and cytokines, such as Il6, in both 
epiWAT and ingWAT of MKO mice. Consistent with the fact that visceral fat depots are 
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often more susceptible to inflammation than subcutaneous fat, the elevated pro-
inflammatory signature in epiWAT was seen already after 4 weeks of HFD feeding. These 
changes were confirmed to specifically occur in the F4/80+ macrophage fraction, but not in 
adipocytes. To support that the changes were specifically caused by GPS2, and not by 
alterations of associated complex subunits, we validated that the expression of Ncor and 
Smrt was not changed in macrophages or adipocytes of epiWAT. We finally demonstrate 
that the transcriptome alterations in GPS2-deficient macrophages provoked a systemic 
increase of the encoded gene products CCL2, IL6, and TNFa upon HFD. Thus, 
macrophage GPS2 likely has a crucial role in limiting metaflammatory responses in the AT 
itself, and in limiting systemic responses originating from AT under conditions of diet-
induced obesity.  
 
Macrophage GPS2-deficiency exacerbates insulin resistance in peripheral tissues during 
diet-induced obesity. 
 
In light of the initially observed correlation between GPS2 levels and insulin resistance 
score upon HFD feeding, we closer investigated glucose homeostasis in MKO versus WT 
mice. We observed that both fasting and feeding blood glucose levels were elevated in 
MKO mice, in conjunction with increased serum insulin levels, suggesting that these mice 
were more insulin-resistant according to the HOMA-IR index. Oral glucose tolerance test 
(OGTT) showed that MKO mice were less glucose-tolerant than WT mice, despite 
increased serum insulin during the glycemic burst. Insulin tolerance test (ITT) confirmed 
that MKO mice became more insulin resistant than WT mice after 12 weeks of HFD. For 
both tests, no changes between WT and MKO mice were detected under control LFD 
conditions.  
 
Taken together, the MKO mouse model-derived results infer a mechanism thereby 
macrophage GPS2 protects against metabolic inflammation of AT, contributes to 
maintaining systemic insulin sensitivity, and prevents ectopic lipid partitioning in the liver 
(steatosis) under conditions of HFD-induced obesity. Overall, the findings of this paper 
suggest a causal relationship between GPS2 expression and function, the extent of tissue 
inflammation, and insulin resistance, which appears conserved in mice and humans (Figure 
11)  
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4.4  Paper IV: Liver-specific loss of GPS2 reveals functions in lipid metabolism and 
NAFLD 
 
Liver GPS2 expression is associated with fibrogenic gene expression in human NASH 
patients. 
 
To explore the potential functions of GPS2 in liver steatosis and fibrosis, we first compared 
the expression of all GPS2 corepressor complex core subunits in non-alcoholic 
steatohepatitis (NASH) transcriptome data from human patients (in collaboration with Dr. 
Bart Staels, INSERM Lille). The analysis in the NASH subjects showed 66 genes were 
positively correlated with GPS2 expression.  Among them were fibrosis genes TGFB, 
TIMP1, ACTA2, TIMP1, and lipogenic gene SCD1. The further analysis showed this gene 
signature was correlated with NCOR, TBL1, TBLR1, and HDAC3, but not with SMRT. 
More datasets were used for the compression in the fibrosis stages, which show GPS2 
expression was positively correlated with fibrosis genes, including TGFB, TIMP1, and 
ACTA2.  GPS2 expression level was high in NASH fibrosis than the non-fibrosis liver 
biopsies. Moreover, the GPS2 level was restored after dietary intervention or gastric bypass 
surgery in the obese human subjects. In summary, the human data indicated that GPS2 
might promote the liver fibrosis and contribute to obesity-associated glucose dysregulation. 
 
Figure 11.  Model linking GPS2, epigenome alterations, and metaflammation. 
 
Reprinted from Nature Medicine, Vol.22. p.780-791, Rongrong Fan et al., Loss of the co-repressor GPS2 sensitizes 
macrophage activation upon metabolic stress induced by obesity and type 2 diabetes, doi: 10.1038/nm.4114, Copyright 
2016, with permission from Springer Nature. 
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Liver-specific Gps2 knockout in mice improves fibrosis and obesity-associated liver 
steatosis and insulin resistance. 
 
We further investigated the causative function of GPS2 in vivo using hepatocyte-specific 
GPS2 knockout mice (LKO). By feeding with methionine- and choline-deficient diet 
(MCD), LKO mice showed improvement of liver fibrosis by significant reduction of serum 
aspartate transaminase (AST) and alanine transaminase (ALT) activity. GPS2 LKO mice 
showed improved obesity-associated liver steatosis and insulin resistance phenotype. When 
treated with a HFD, LKO mice body weight was significantly lower than the control group. 
Oral glucose tolerance test (OGTT) and insulin tolerance test (ITT) showed improved 
insulin sensitivity and glucose control. Consistently, both serum VLDL, total triglyceride 
levels and intra-hepatic triglyceride levels were decreased in LKO mice. These results 
indicated that GPS2 in hepatocyte plays a crucial role in both lipid metabolism and glucose 
homeostasis. 
 
PPARa is a direct target of GPS2 in the liver. 
 
In order to explore mechanisms involved in the regulatory role of GPS2 in the liver, we 
analyzed the GPS2 LKO RNA-seq data and identified PPARa pathways target genes were 
enriched by GPS2 depletion. We further performed the GPS2 ChIP-seq to obtain cistrome 
profiles in the liver. Consistent with the transcriptome data, TF binding motif analysis 
revealed PPAR binding sites among the top GPS2-occupied sites.  To test the requirement 
of PPARa for the GPS2 repression of lipid metabolic genes, we generated GPS2 and 
PPARa double KO (PGKO) mice. The elevated lipid oxidation observed in LKO mice was 
not observed in PGKO mice, as indicated by unchanged fed and fasted ketone body 
generation, which suggests that GPS2 repression of lipid oxidation was dependent on 
PPARa. Consistently, qRT-PCR showed that GPS2 ablation did not induce the PPARa 
target genes Pdk4, Cyp4a14, Fgf21 in PGKO livers. Collectively, these data identify 
PPARα as a likely target TF for GPS2 in the liver. 
 
GPS2 cooperates with NCOR to modulate liver epigenome and transcriptome. 
 
To define the GPS2-dependent cistrome and epigenome in mouse liver, we performed 
ChIP-seq of GPS2 along with H3K27ac and H3K4me3 in WT and LKO mice. Comparison 
of the GPS2-dependent transcriptome (RNA-Seq) and epigenome (H3K27ac and H3K4me3) 
revealed that transcriptional and epigenetic activation (i.e., changes in activating histone 
modifications) at GPS2-sensitive gene loci are highly coordinated. Consistent with the lack 
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of gene expression changes, H3K27ac levels at GPS2-sensitive gene loci were similar in 
PGKO mice compared to PKO mice, which indicated the epigenetic activation of these 
genes upon GPS2 depletion was dependent on PPARa. We further investigated whether 
GPS2 functions within the corepressor complex to modulate liver gene expression. 
Cistrome analysis revealed that GPS2, NCOR, SMRT are present at promoters and 
enhancers of PPARa target genes including Pdk4 and Cyp4a14. However, KEGG pathway 
analysis of the genes co-repressed by GPS2 and NCOR revealed PPAR signaling in the top 
list, along with liver metabolic pathways, which was not observed for other genes co-
repressed by GPS2 and SMRT. In sum, the above data suggest that GPS2 repression of 
PPARa target genes in hepatocytes involves functional cooperation with NCOR, while the 
loss of GPS2 in LKO mice results in epigenome remodeling of the corresponding 
promoter/enhancer regions leading to PPARa target gene activation. 
 
In conclusion, this study identifies GPS2 as an epigenome modifier and PPARa 
corepressor in hepatocytes that inhibition has the therapeutic potential to reverse the 
progression of NASH toward fibrosis. The proposed link of GPS2 to NCOR in hepatocytes 
raises questions as to the different corresponding KO phenotypes (Figure 12). While Gps2  
LKO resulted in improved liver steatosis and reduced lipid accumulation, NCOR LKO 
resulted in the opposite, i.e., increased lipid accumulation [160, 161].  
Figure 12.  Model highlighting the putative role of GPS2 in fatty liver disease. 
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5 CONCLUDING REMARKS AND  PERSPECTIVES 
 
The four studies in this thesis have focused on the roles of GPS2 in obesity/T2D-related 
inflammation and lipid/cholesterol metabolism, which elaborated potential GPS2-mediated 
mechanisms that link epigenome alterations and metabolic disease. To this end, this thesis 
used both in vitro and in vivo models to investigate the function of GPS2 in closely linked 
inflammatory and metabolic signaling pathways. The in vitro studies not only enabled us to 
verify and test potential mechanisms underlying the phenotypes of the Gps2 knockout mice 
but they also resulted in new complementary findings that would have been difficult to 
detect in vivo.  
 
The probably most critical finding in this thesis is that GPS2 inhibits the transcription of 
crucial pro-inflammatory enhancers and genes such as Ccl2 in macrophages. Thereby, 
GPS2 plays pivotal roles in counteracting inflammation in the context of obesity and T2D. 
Intriguing mechanistic results of this thesis are that this anti-inflammatory function of 
GPS2 in macrophages requires cooperation with SMRT, while the metabolic function in the 
liver requires cooperation with NCOR. Although the reasons for this cell type-selective 
cooperativity are currently unknown, the data suggest that GPS2 functions within 
corepressor sub-complexes, a hitherto unrecognized feature of this essential epigenome 
modifier [66]. Additionally, GPS2 also works ‘out of complex’ to induce ABCA1 
expression linked to cholesterol efflux from macrophages, indicating that there is a fraction 
of ‘free’ GPS2 involved in repression-independent transcriptional regulation.        
 
The key results of this thesis may help to better understand mechanisms underlying the 
development, prevention and treatment of metaflammatory diseases, in particular, obesity-
associated T2D and atherosclerosis.  
 
In Study I, we demonstrate that GPS2 displays a unique function in controlling endotoxin 
(LPS)-induced macrophage cholesterol efflux via ABCA1. We also provide evidence that 
the GPS2-ABCA1 pathway is conserved in mouse and human macrophages. Thus, the 
study contributes to better understanding the macrophage-mediated pathways that link 
obesity-associated inflammation, T2D, and cholesterol efflux to the development of 
cardiovascular diseases. More specifically, our results should help to re-interpret the 
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involvement of GPS2 and ABCA1 in mechanisms of anti-inflammatory trans-repression by 
LXRs  [82, 162-166]. This may stimulate the future investigation of anti-inflammatory drug 
candidates that modulate the GPS2-ABCA1-LXR axis.    
 
In Study II, we uncover molecular features of GPS2-repressed inflammatory enhancers, 
with a particular emphasis on the Ccl2 super-enhancer that controls metaflammation both 
locally in the adipose tissue and systemically. Macrophage-derived CCL2 is a major 
chemokine and drug target involved in recruiting immune cells to metabolic tissues, leading 
to peripheral insulin resistance [36, 167]. We additionally provide evidence that enhancer-
transcribed eRNAs may have a function, which would be a significant advance in the field. 
Future efforts should attempt to specifically target eRNAs via antisense LNAs in vivo, for 
example in obese mouse models. This would provide in vivo validation of eRNA function 
and describe pre-clinical models for future eRNA-targeted therapies. Indeed, the feasibility 
of targeting tissue-specific and disease-relevant enhancers using LNA or CRISPR-based 
strategies might have clinical importance [168, 169].  
 
In Study III, we demonstrate that macrophage-specific Gps2 knockout mice display the 
hallmarks of metaflammation typical for humans with obesity and/or T2D. The in vivo 
mouse model and the in vitro studies using isolated macrophages provide strong support for 
the suspected causal role of GPS2 dysregulation in driving epigenome alterations linked to 
metaflammation in humans. The underlying mechanisms identified in this study suggest 
therapeutic possibilities for delaying or reversing obesity/T2D-related inflammation 
through the restoration of GPS2 expression and function. Although GPS2 protein itself is 
currently unlikely to be a feasible target for drug development, the modulation of protein-
protein interactions or of post-translational modifications may offer alternatives.      
 
In Study IV, we show that liver-specific Gps2 knockout in mice improves obesity-
associated liver steatosis and insulin resistance. These results, along with expression 
correlation analysis in human liver samples and the identification of PPARα as target TF, 
suggest that the modulation of the GPS2-PPARα network could help to restore altered lipid 
metabolism and glucose homeostasis in NAFLD. 
 
Overall, this thesis puts forward the concept of a ‘GPS2 dysfunction-epigenome alterations-
metaflammatory disease’ axis, which should be further employed mechanistically and 
therapeutically in different cell types and signaling contexts.   
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